Rangeley Capital’s Elevation Oncology ELEV Stock Holding History

Rangeley Capital’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-905,289	Closed	-$332K	–	131
2025 Q2	$332K	Buy	+905,289	New	+$302K	0.4%	39

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Rangeley Capital's ELEV Position: Q3 2025 in Review

Rangeley Capital sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 905,289 shares — an estimated $332K sold.

Rangeley Capital first reported a position in ELEV in Q2 2025 and held it in 1 quarter. The position peaked at $332K in Q2 2025. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Rangeley Capital reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Rangeley Capital sold 905,289 Elevation Oncology shares in Q3 2025, an estimated $332K.
Rangeley Capital first reported a position in Elevation Oncology in Q2 2025 and held it in 1 quarter.
Rangeley Capital's Elevation Oncology position peaked at $332K in Q2 2025.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Rangeley Capital's 13F filing for Q3 2025, filed 14 Nov 2025.